New hope for leukemia patients who Can't tolerate standard treatment
NCT ID NCT02717611
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called ACP-196 (acalabrutinib) in 60 adults with chronic lymphocytic leukemia (CLL) whose cancer returned or didn't respond to treatment and who had to stop ibrutinib because of side effects. The main goal is to see how many patients have their tumors shrink or disappear. Participants take the drug by mouth, and researchers track how long the benefits last and any side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Tucson, Arizona, 85704, United States
-
Research Site
Concord, California, 94520, United States
-
Research Site
La Jolla, California, 92093, United States
-
Research Site
Palo Alto, California, 94304, United States
-
Research Site
Washington D.C., District of Columbia, 20007, United States
-
Research Site
Chicago, Illinois, 60611, United States
-
Research Site
Lake Success, New York, 11042, United States
-
Research Site
New York, New York, 10021, United States
-
Research Site
Columbus, Ohio, 43210, United States
-
Research Site
Nashville, Tennessee, 37203, United States
-
Research Site
Houston, Texas, 77030, United States
-
Research Site
Sherman, Texas, USA, United States
-
Research Site
Seattle, Washington, 98108, United States
-
Research Site
Seattle, Washington, 98122, United States
-
Research Site
Spokane, Washington, 99208, United States
-
Research Site
Milwaukee, Wisconsin, 53226, United States
-
Research Site
Bruges, 8000, Belgium
-
Research Site
Bordeaux, 33076, FR, France
-
Research Site
Haifa, 31000, Israel
-
Research Site
Madrid, 28006, Spain
-
Research Site
Bournemouth, BH7 7DW, United Kingdom
-
Research Site
Leeds, LS9 7TF, United Kingdom
-
Research Site
Manchester, M20 4BX, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Can a Three-Drug combo outsmart High-Risk CLL?
- Can a gentler dose of zanubrutinib keep CLL at bay in the very elderly?
- Can a Two-Drug combo wipe out hidden leukemia cells?
- Can a Chemo-Free pill combo outsmart leukemia at first diagnosis?